Journal article · 2019 · Open access

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

Btissame El Hassouni, Giulia Mantini, Giovanna Li Petri, Mjriam Capula, Lenka N.C. Boyd, Hannah N. W. Weinstein, Andrea Vallés‐Martí, Mathilde C.M. Kouwenhoven, Elisa Giovannetti, Bart A. Westerman, Godefridus J. Peters, on Behalf of the EORTC PAMM Group

Anticancer Research, 39(7), 3303–3309 · Published 1 July 2019 · DOI 10.21873/anticanres.13472

Free PDFView at the publisherCite this paper

In brief

“To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology” is a 2019 journal article by Btissame El Hassouni and 11 co-authors, published in Anticancer Research. OpenAlex counts 38 citations as of 16 November 2026. It is open access: the full text is free to read at Anticancer Research.

Citations
38
Most cited in
2023 (9)
Field-weighted impact
1.02
References
24
Authors
12

Abstract

Combination therapies are used in the clinic to achieve cure, better efficacy and to circumvent resistant disease in patients. Initial assessment of the effect of such combinations, usually of two agents, is frequently performed using in vitro assays. In this review, we give a short summary of the types of analyses that were presented during the Preclinical and Early-phase Clinical Pharmacology Course of the Pharmacology and Molecular Mechanisms Group, European Organization for Research and Treatment on Cancer, that can be used to determine the efficacy of drug combinations. The effect of a combination treatment can be calculated using mathematical equations based on either the Loewe additivity or Bliss independence model, or a combination of both, such as Chou and Talalay's median-drug effect model. Interactions can be additive, synergistic (more than additive), or antagonistic (less than additive). Software packages CalcuSyn (also available as CompuSyn) and Combenefit are designed to calculate the extent of the combined effects. Interestingly, the application of machine-learning methods in the prediction of combination treatments, which can include pharmacogenomic, genetic, metabolomic and proteomic profiles, might contribute to further refinement of combination regimens. However, more research is needed to apply appropriate rules of machine learning methods to ensure correct predictive models.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

El Hassouni, B., Mantini, G., Petri, G. L., Capula, M., Boyd, L. N., Weinstein, H. N. W., Vallés‐Martí, A., Kouwenhoven, M. C., Giovannetti, E., Westerman, B. A., Peters, G. J., & on Behalf of the EORTC PAMM Group. (2019). To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Research, 39(7), 3303–3309. https://doi.org/10.21873/anticanres.13472

MLA 9

El Hassouni, Btissame, et al. “To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.” Anticancer Research, vol. 39, no. 7, 2019, pp. 3303–3309. https://doi.org/10.21873/anticanres.13472.

Chicago

El Hassouni, Btissame, Giulia Mantini, Giovanna Li Petri, Mjriam Capula, Lenka N.C. Boyd, Hannah N. W. Weinstein, Andrea Vallés‐Martí, et al. 2019. “To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.” Anticancer Research 39 (7): 3303–3309. https://doi.org/10.21873/anticanres.13472.

Harvard

El Hassouni, B. et al. (2019) ‘To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology’, Anticancer Research, 39(7), pp. 3303–3309. doi:10.21873/anticanres.13472.

IEEE

B. El Hassouni et al., “To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology,” Anticancer Research, vol. 39, no. 7, pp. 3303–3309, 2019, doi: 10.21873/anticanres.13472.

BibTeX

@article{elhassouni2019combine,
  title     = {{To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology}},
  author    = {El Hassouni, Btissame and Mantini, Giulia and Petri, Giovanna Li and Capula, Mjriam and Boyd, Lenka N.C. and Weinstein, Hannah N. W. and Vallés‐Martí, Andrea and Kouwenhoven, Mathilde C.M. and Giovannetti, Elisa and Westerman, Bart A. and Peters, Godefridus J. and on Behalf of the EORTC PAMM Group},
  journal   = {Anticancer Research},
  year      = {2019},
  volume    = {39},
  number    = {7},
  pages     = {3303--3309},
  doi       = {10.21873/anticanres.13472},
  url       = {https://doi.org/10.21873/anticanres.13472}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202011
202177
202233
202399
202499
202577
202622

Its field-weighted citation impact is 1.02: it has been cited 1.02 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • drug interactions
  • combination therapy
  • synergistic effect
  • antagonism
  • additivity
  • Bliss independence model
  • pharmacogenomics
  • cancer chemotherapy

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

El Hassouni, B., Mantini, G., Petri, G. L., Capula, M., Boyd, L. N., Weinstein, H. N. W., Vallés‐Martí, A., Kouwenhoven, M. C., Giovannetti, E., Westerman, B. A., Peters, G. J., & on Behalf of the EORTC PAMM Group. (2019). To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. Anticancer Research, 39(7), 3303–3309. https://doi.org/10.21873/anticanres.13472

How many times has this paper been cited?

38 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Anticancer Research.

Who wrote this paper?

Btissame El Hassouni, Giulia Mantini, Giovanna Li Petri, Mjriam Capula, Lenka N.C. Boyd, Hannah N. W. Weinstein, Andrea Vallés‐Martí, Mathilde C.M. Kouwenhoven, Elisa Giovannetti, Bart A. Westerman, Godefridus J. Peters, on Behalf of the EORTC PAMM Group.

What is the DOI of this paper?

10.21873/anticanres.13472. The permanent link is https://doi.org/10.21873/anticanres.13472.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.